United Therapeutics Executive and Leadership Team

Harsh Hurkat, the Senior Analyst - Chief Financial Officer Org at United Therapeutics, directs financial analysis and reporting functions. This role involves detailed examination of financial data to support strategic decision-making and operational efficiency. Hurkat's responsibilities include forecasting financial performance, managing budgets, and identifying cost-saving opportunities. The Senior Analyst - Chief Financial Officer Org ensures the accuracy of financial statements and compliance with regulatory requirements. This position contributes to the overall financial health and stability of the organization by providing critical insights into market trends and investment opportunities. Harsh Hurkat's analytical expertise underpins the company's fiscal strategy, enabling informed resource allocation and risk management across all departments. The focus remains on optimizing financial operations and supporting long-term growth objectives through rigorous data analysis and strategic financial planning.

James Edgemond, the Chief Financial Officer & Treasurer at United Therapeutics, directs the company's financial strategy, fiscal management, and treasury operations. This executive role encompasses comprehensive oversight of financial planning, budgeting, accounting, and investment activities. Edgemond is responsible for ensuring the financial integrity and stability of the organization, managing capital allocation, and optimizing financial performance. The Chief Financial Officer & Treasurer works to secure funding, manage banking relationships, and oversee all financial transactions, including those related to the company's advanced manufacturing capabilities and biotechnology ventures. James Edgemond's leadership ensures compliance with financial regulations and reporting standards, providing critical financial insights to support strategic growth and operational expansion. This position is fundamental to maintaining the company's financial health, driving profitability, and supporting the development of life-saving therapies through robust financial stewardship and strategic capital deployment.

Michael Benkowitz, the President & Chief Operating Officer at United Therapeutics, orchestrates daily operations and drives strategic execution across the organization. This leadership position involves overseeing all functional departments, ensuring seamless integration and efficient workflow. Benkowitz's mandate includes optimizing operational processes, enhancing productivity, and maintaining the highest standards of quality and compliance, particularly in the context of pharmaceutical manufacturing and sterile unit-dose production. The President & Chief Operating Officer works closely with other senior leaders to align operational strategies with the company's mission of developing innovative therapies. Michael Benkowitz's oversight extends to managing resources, implementing best practices, and fostering a culture of continuous improvement. This role is pivotal in translating the company's vision into tangible operational success, ensuring the efficient delivery of products and services to patients and clients worldwide. The focus is on driving operational excellence and supporting the company's growth initiatives through effective management and strategic oversight.

Michael Callahan, the President, UT Division of Cellular Therapeutics at United Therapeutics, spearheads the strategic direction and operational execution for the company's cellular therapy initiatives. This leadership role focuses on advancing novel treatments derived from cellular and tissue engineering, aiming to address unmet medical needs. Callahan oversees the research, development, and commercialization efforts within this specialized division, ensuring alignment with the company's broader mission of improving patient lives. The President, UT Division of Cellular Therapeutics drives innovation in regenerative medicine and cell-based drug delivery systems. Michael Callahan's expertise is crucial in navigating the complex scientific and regulatory landscape of cellular therapies, fostering collaborations, and securing resources to accelerate program development. This position is instrumental in positioning United Therapeutics at the forefront of advanced biotechnological treatments and expanding its impact in critical therapeutic areas.

Jeff Ross, the President at United Therapeutics, holds a broad leadership mandate focused on driving the company's strategic initiatives and operational success. This executive position involves overseeing key business functions and ensuring the effective implementation of corporate strategies across various divisions. Ross works to enhance the company's market position and operational efficiency, particularly in its specialized areas of pharmaceutical manufacturing and biotechnology development. The President collaborates with other senior leaders to foster innovation, optimize resource allocation, and maintain high standards of quality and compliance. Jeff Ross's leadership contributes to the company's overall growth and its mission to develop groundbreaking therapies that improve patient lives. This role is central to guiding United Therapeutics through evolving market dynamics and ensuring its continued impact in delivering advanced healthcare solutions globally.

Michael Md Dtmh, the President, UT Division of Cellular Therapeutics at United Therapeutics, leads the strategic vision and operational management for the company's cellular therapy programs. This executive role is dedicated to advancing innovative treatments in regenerative medicine and cell-based therapies. Md Dtmh oversees the research, development, and clinical translation of cellular products, ensuring they meet rigorous scientific and regulatory standards. The President, UT Division of Cellular Therapeutics drives the integration of advanced biotechnological approaches to address critical unmet medical needs. Michael Md Dtmh's expertise is crucial in navigating the complex landscape of cellular therapy development, fostering scientific collaboration, and positioning the division for future growth. This leadership is essential for United Therapeutics' commitment to pioneering transformative treatments and expanding its impact in the field of advanced cellular medicine.

Jeffrey Kase, the Vice President, Chief Information Officer at United Therapeutics, leads the company's information technology strategy and infrastructure. This critical role involves overseeing all aspects of technology, including digital transformation, cybersecurity, data management, and system integration across manufacturing, research, and administrative functions. Kase is responsible for ensuring that technology solutions support the company's mission of developing innovative pharmaceutical products and improving patient outcomes. The Vice President, Chief Information Officer drives the implementation of advanced IT systems that enhance operational efficiency, data security, and regulatory compliance, particularly concerning sensitive patient and proprietary manufacturing data. Jeffrey Kase's strategic vision ensures that United Therapeutics leverages technology effectively to maintain its leadership in areas like blow-fill-seal technology and sterile unit-dose production. This position is essential for enabling data-driven decision-making and supporting the company's global operations through robust and secure technological frameworks.

Gil Golden, the Chief Medical Officer at United Therapeutics, directs the company's clinical development strategies and medical affairs. This executive position is central to advancing the company's pipeline of innovative therapies, particularly in areas like cellular therapeutics and lung biotechnology. Golden oversees the design and execution of clinical trials, ensuring adherence to ethical standards and regulatory requirements set by bodies such as the FDA and EMA. The Chief Medical Officer provides critical medical expertise, guiding research efforts and evaluating the therapeutic potential of new drug candidates. Gil Golden's leadership ensures that clinical programs are aligned with patient needs and the company's strategic objectives, contributing significantly to the development of life-saving treatments. This role is vital for translating scientific discoveries into viable medical solutions and maintaining the company's commitment to improving patient health through advanced pharmaceutical and biotechnological innovation.

Alyssa Friedrich, the Executive Vice President & Chief People Officer at United Therapeutics, leads the company's human capital strategy and organizational development. This executive role encompasses talent acquisition, employee engagement, compensation and benefits, and fostering a positive and productive work environment. Friedrich is responsible for aligning people strategies with the company's business objectives, ensuring that United Therapeutics attracts, develops, and retains top talent essential for its innovative pharmaceutical and biotechnology operations. The Executive Vice President & Chief People Officer champions a culture of collaboration, diversity, and inclusion, supporting the company's mission to develop life-saving therapies. Alyssa Friedrich's leadership ensures that the organization's most valuable asset—its people—are empowered to drive innovation and achieve excellence in areas such as advanced manufacturing and clinical research. This position is critical for building a strong organizational foundation that supports sustained growth and scientific advancement.

Marc Lorber, the Senior Vice President and Chief Medical Officer, Lung Biotechnology, PBC at United Therapeutics, directs critical medical and scientific endeavors within the company's lung biotechnology division. This specialized role focuses on advancing therapies and innovative solutions for pulmonary diseases. Lorber oversees clinical research, medical strategy, and regulatory affairs pertinent to lung-specific treatments, ensuring alignment with the company's overarching mission. The Senior Vice President and Chief Medical Officer, Lung Biotechnology, PBC provides essential medical expertise to guide the development of novel therapeutic agents and drug delivery systems. Marc Lorber's leadership is pivotal in translating cutting-edge research into tangible patient benefits, driving progress in areas such as xenotransplantation and advanced lung therapies. This position is fundamental to United Therapeutics' commitment to pioneering treatments and improving the quality of life for individuals with respiratory conditions.